Researchers reported that they could induce pluripotency from blood cells. It just so happened that RUCDR was ... Suddenly, the opportunities for iPSC derivation and banking seemed endless. The ...

From the above analysis, we conclude that a bank of pluripotent stem cell lines with HLA-A, HLA-B and HLA-DR haplotypes is feasible and would cover a large majority of the Japanese population.

Pluripotent stem cells are dynamic, respond rapidly to the ... the quality and stability of the hESC master cell bank must also be assured. Rather than adding an unnecessary burden or delaying ...

Two small clinical trials tested the safety of injecting stem cells into the brains of Parkinson's patients and found no adverse effects ...

Understanding how cells differentiate during early embryonic development is crucial for advancing regenerative medicine and ...

Most of the human induced pluripotent stem cells stored at major cell line repositories and ... The sequencing revealed that 72 percent of the skin cell–derived hiPSCs in the HipSci bank showed signs ...

The Stem Cell Core provides access to a streamlined, IRB-approved consenting process for acquisition of patient samples and generation of pluripotent stem cells and stem cell-derivatives for basic and ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

StemBANCC aims to use human-induced pluripotent stem cells as research tools for drug discovery with the goal of using this ground-breaking new technology to develop human disease models and ...

Induced pluripotent stem cells (iPSCs) are a hopeful alternative for analyzing antigen expression in vitro and developing novel cellular therapies. iPSCs have been derived from differentiated ...

The papers, published in Nature this week, investigate the use of cells derived from human induced pluripotent stem cells and human embryonic stem cells, respectively. However, further research is ...

Our group examines the hereditary causes of growth and development using human pluripotent stem cells. We model rare diseases and develop evidence-based treatments for patients with delayed puberty.